Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel
- Citation:
- Clin Genitourin Cancer vol 18 (3) 222-229.e2
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Book Volume:
- 9
- Parents:
- 2684
- Children:
- None
- Pharmas:
- Genentech
- Grants:
- R21 CA195424-01, U10CA180821, U10CA180882, W81XWH-15-1-0467; P30 CA 008748, U24CA196171
- Corr. Author:
- Authors:
- Charles J Ryan Sandipan Dutta William K Kelly Rob Middleberg Carly Russell Michael J. Morris Mary-Ellen Taplin Susan Halabi
- Networks:
- CA824, LAPS-MA036, LAPS-NY016, MN022
- Study
- CALGB-90401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Androgens, Metastatic Castration-Resistant Prostate Cancer, Testosterone, Prognostic biomarker Docetaxel